{"database":"ecrin-mdr-crc","file_versions":[],"scores":null,"additional":{"omics_type":["Clinical"],"study_start_year":["2018"],"condition":["colorectal cancer"],"disease":["Colorectal Cancer"],"study_type":["Interventional"],"full_dataset_link":["https://newmdr.ecrin.org/Study/2646378"],"location":["Japan"],"study_start_month":["3"],"repository":["ECRIN MDR"],"study_status":["Completed"],"additional_accession":[]},"is_claimable":false,"name":"A multicenter phase II study of eribulin monotherapy in patients with BRAF V600E mutant metastatic colorectal cancer","description":"Interventions: Eribulin is administered intravenously at a dose of 1.4mg/m^2/day on Days 1 and 8, repeated every 21 days.\nPrimary outcome(s): Confirmed objective response rate(ORR) by investigators’ assessment\nStudy Design: Single arm Non-randomized","dates":{"creation":"2018-03-15"},"accession":"2646378","cross_references":{"Japan Primary Registries Network":["JPRN-UMIN000031221"]}}